| content | |||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Asoprisnil
|
|
| Systematic (IUPAC) name | |
| rel-4-[(8R,11S,13R,14R,17R)-17-Methoxy-17-
(methoxymethyl)-13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro- 1H-cyclopenta[a]phenanthren-11-yl]benzaldehyde oxime |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C28H35NO4 |
| Mol. mass | 449.582 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone sensitive myomata.1
In 2005, Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed.2
References
- ^ DeManno D, Elger W, Garg R, et al (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids 68 (10-13): 1019–32. doi:. PMID 14667995.
- ^ Schering Interim Report Q1-3 2005
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
